Anebulo Pharmaceuticals (FRA:214) Shares Outstanding (EOP): 41.09 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:214 Anebulo Pharmaceuticals Inc FRA:214
35 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals Shares Outstanding (EOP)?

Anebulo Pharmaceuticals FRA:214 35 Shares Outstanding (EOP) is 41.09 Mil as of Dec. 2025. GuruFocus rates FRA:214 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Anebulo Pharmaceuticals's shares outstanding for the quarter that ended in Dec. 2025 was 41.09 Mil.

Anebulo Pharmaceuticals's quarterly shares outstanding stayed the same from Sep. 2025 (41.09 Mil) to Dec. 2025 (41.09 Mil).

Anebulo Pharmaceuticals's annual shares outstanding increased from Jun. 2024 (25.93 Mil) to Jun. 2025 (41.09 Mil). It means Anebulo Pharmaceuticals issued new shares from Jun. 2024 to Jun. 2025 .


Anebulo Pharmaceuticals  (FRA:214) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Anebulo Pharmaceuticals Shares Outstanding (EOP) Related Terms


Anebulo Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals Shares Outstanding (EOP) Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (EOP)
Get a 7-Day Free Trial 23.35 23.35 25.63 25.93 41.09

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.09 41.09 41.09 41.09 41.09

FRA:214 vs PHIO, COCP, CALC: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Shares Outstanding (EOP) falls into.


FRA:214
35GF Score
Anebulo Pharmaceuticals Inc FRA:214
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 41.09 Mil mean?
Anebulo Pharmaceuticals (FRA:214) has a Shares Outstanding (EOP) of 41.09 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Anebulo Pharmaceuticals and its competitors.
Is Anebulo Pharmaceuticals' Shares Outstanding (EOP) too high?
Anebulo Pharmaceuticals' current Shares Outstanding (EOP) is 41.09 Mil. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Shares Outstanding (EOP) compare to PHIO and COCP?
Anebulo Pharmaceuticals' Shares Outstanding (EOP) of 41.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Anebulo Pharmaceuticals and its competitors. Anebulo Pharmaceuticals's current Shares Outstanding (EOP) is 41.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (FRA:214) has a current Shares Outstanding (EOP) of 41.09 Mil. The current Shares Outstanding (EOP) is 41.09 Mil. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Anebulo Pharmaceuticals (FRA:214), the current Shares Outstanding (EOP) is 41.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Other Exchanges ANEB:USA
Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for FRA:214

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price